Department of Radiology, Northwestern University, 737 N. Michigan Ave, Suite 1600, Chicago, IL, 60611, USA.
Cardiovasc Toxicol. 2019 Oct;19(5):482-484. doi: 10.1007/s12012-019-09521-0.
An increasing volume of pre-clinical and clinical-translational research is attempting to identify novel biomarkers for improved diagnosis and risk-stratification of chemotherapy-induced cardiotoxicity. Most published animal models have employed weekly intraperitoneal injections of doxorubicin to reach a desired cumulative dose. This approach can be associated with severe systemic toxicity which limits the animal model usefulness, particularly for advanced imaging. In the current study, slow-release subcutaneous doxorubicin pellets demonstrated histopathologic evidence of cardiotoxicity at doses similar to standard human dose-equivalents without limiting animal survival or ability to participate in advanced imaging studies. This approach may provide a more robust cardiotoxicity animal model.
越来越多的临床前和临床转化研究试图确定新的生物标志物，以改善化疗诱导性心脏毒性的诊断和风险分层。大多数已发表的动物模型都采用每周腹腔内注射多柔比星，以达到所需的累积剂量。这种方法可能与严重的全身毒性相关，限制了动物模型的实用性，特别是在先进的成像方面。在本研究中，缓释放皮下多柔比星微球在剂量与标准人类剂量等效相似的情况下显示出心脏毒性的组织病理学证据，而不会限制动物的生存或参与先进成像研究的能力。这种方法可能为心脏毒性动物模型提供更有力的证据。
